Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 14/20 | 0.57 |
| ▸ | TOP2A | P11388 | 1/20 | 0.57 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953217 | 0.93 | ALDH1A1 (0.52) | SLC2A1TOP2ASLC2A2ALDH1A1NPC1 | |
| SCHEMBL1430433 | 0.90 | CYP1A2 (0.52) | SLC2A1TOP2AALDH1A1NPC1RAB9A | |
| SCHEMBL7655591 | 0.87 | ALDH1A1 (0.52) | SLC2A1ALDH1A1NPC1RAB9A | |
| SCHEMBL15332593 | 0.82 | SLC2A1 (0.51) | SLC2A1ALDH1A1NPC1RAB9A | |
| SCHEMBL1431015 | 0.82 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9A | |
| SCHEMBL29951865 | 0.82 | NPC1 (0.52) | ALDH1A1NPC1RAB9A | |
| SCHEMBL1430465 | 0.82 | NPC1 (0.74) | SLC2A1ALDH1A1NPC1RAB9A | |
| SCHEMBL15330868 | 0.80 | ALDH1A1 (0.63) | SLC2A1ALDH1A1NPC1RAB9A | |
| SCHEMBL15332057 | 0.80 | ALDH1A1 (0.46) | SLC2A1ALDH1A1NPC1RAB9A | |
| SCHEMBL29956631 | 0.79 | NPC1 (0.51) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| EP-3004088-A1 | SLC2A TRANSPORTER INHIBITORS | Iomet Pharma Ltd. (GB) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014187922-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | SLC2A1 6/4885TOP2A 898/4885SLC2A2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.